Distribution of *Kingella kingae* Capsular Serotypes in France Assessed by a Multiplex PCR Assay on Osteoarticular Samples

Romain Basmaci,^{a,b,c} Philippe Bidet,^{b,c,d} Cindy Mallet,^e Raphaël Vialle,^{f,g} Stéphane Bonacorsi^{b,c,d}

^aService de Pédiatrie-Urgences, Hôpital Louis-Mourier, AP-HP, Colombes, France

^bIAME, UMR 1137, INSERM, Paris, France

^cUniversité Paris-Diderot, Sorbonne Paris Cité, Paris, France

^dService de Microbiologie, Centre National de Référence associé *Escherichia coli*, Hôpital Robert-Debré, AP-HP, Paris, France

^eService de Chirurgie Orthopédique Pédiatrique, Hôpital Robert-Debré, AP-HP, Paris, France

^fService de Chirurgie Orthopédique et Réparatrice de l'Enfant, Hôpital Armand Trousseau, AP-HP, Paris, France

^gSorbonne Université, Paris, France

KEYWORDS *Kingella kingae*, capsule, typing, epidemiology, pathophysiology

Kingella kingae is the leading pathogen of osteoarticular infection (OAI) in <4-year-old children in different countries where improved culture methods and nucleic acid amplification assays are routinely employed (1). The oropharynx is recognized as the portal of entry for *K. kingae*, which can penetrate the bloodstream and invade distant organs, facilitated by several virulence factors, such as a recently described polysaccharide capsule (2). From an international collection of 150 invasive and carriage isolates from 10 countries, Porsch et al. (2) have described four capsule types using a multiplex PCR approach. Over 95% of invasive isolates in the collection were types a or b, while capsule types c and d were more commonly observed among carriage isolates (2, 3). This distribution was described based on *K. kingae* isolates; however, *K. kingae* is a fastidious bacterium, and whether strains harboring capsule types a or b can be more easily cultivated from clinical samples is unknown. Such differences may lead to biased epidemiological results. Moreover, among this collection, 30 invasive isolates were from France, mainly isolated from 2010 to 2013 ($n = 24/30$, date range 1972 to 2013). To our knowledge, no more recent data are available yet, and whether the epidemiology has changed remains to be determined.

We aimed to describe the *K. kingae* capsule serotypes using a multiplex PCR protocol, as recently described (4), on a fraction of our collection of osteoarticular samples, which were positive with the *K. kingae* specific real-time PCR used as routine in our laboratory (5).

From July 2013 to April 2018, we found 115 *K. kingae*-positive osteoarticular samples from 105 patients (1 to 3 samples per patient). Sample origins were joint fluid (95/105; 90.5%), synovial biopsy specimen (8/105; 7.6%), bone abscess (1/105; 0.9%), and subcutaneous collection (1/105; 0.9%). Capsular PCR allowed unambiguously identification of a capsule type in all of these 115 samples (Fig. 1).

Among the 105 patients, the PCR results showed 71 (67.6%) type a capsules, 33 (31.4%) type b capsules, 1 (0.9%) type c capsule, and no type d capsules. When multiple samples were available for one patient, the results were identical for each sample. There were no significant variations between distribution of type a and b

Accepted manuscript posted online 3 October 2018

Citation Basmaci R, Bidet P, Mallet C, Vialle R, Bonacorsi S. 2018. Distribution of *Kingella kingae* capsular serotypes in France assessed by a multiplex PCR assay on osteoarticular samples. J Clin Microbiol 56:e01491-18. <https://doi.org/10.1128/JCM.01491-18>.

Editor Robin Patel, Mayo Clinic

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Romain Basmaci, romain.basmaci@aphp.fr.

FIG 1 Gel electrophoresis of the *Kingella kingae* multiplex capsular PCR in osteoarticular samples. The molecular weight is related to the capsule serotype; a, b, c, and d types are identified from the highest to the lowest molecular weights, respectively (lane 4). Capsule type a was identified in 4 samples (lanes 1, 6, 7, and 8), capsule type b was identified in 2 samples (lanes 3 and 5), and capsule type c was identified in 1 sample (lane 2). Lane 9, sterile water; lane 10, DNA ladder.

capsules during the study period or by age or by whether the culture was positive or negative (Table 1).

In a large collection of *K. kingae*-positive osteoarticular samples in France, we demonstrated that our capsular PCR is able to identify the capsular serotypes of invasive *K. kingae* in skeletal system specimens. Knowing that *rtxA*, *rtxB*, and *cpn60* PCRs cannot discriminate *K. kingae* from *Kingella negevensis* and *Simonsiella muel-leri*, respectively, it may be suggested that adding the capsular PCR to the molecular diagnosis may increase its specificity (4). We observed that 99% of *K. kingae* OAI involved a strain harboring a capsule type a or b, which is similar to that observed in the Israeli and international collections of invasive isolates (2, 3). Our results strengthen the hypothesis that the types a and b capsules may have enhanced pathogenic properties. Polysaccharide capsules are a common target for development of vaccines, such as pneumococcal vaccines; the implication of capsules a and b in *K. kingae* invasive infections could be of high interest for the development of a *K. kingae* vaccine. On the other hand, very few data on the distribution of capsule serotypes among carriage isolates are yet available. In a recent study, it was described that types a and b were predominant in a small population of healthy children carrying *K. kingae* in France (4). A better characterization of the distribution of *K. kingae* capsular serotypes among healthy carriers would lead to better

TABLE 1 Distribution of capsule types among 105 patients with *K. kingae* osteoarticular infection

Parameter	Total no. (n = 105)	No. (%) for capsule type:		
		a	b	c
<i>n</i>	105	71	33	1
Year				
2013	24	19 (79.2)	5 (20.8)	0
2014	13	8 (61.5)	5 (38.5)	0
2015	0			
2016	19	10 (52.6)	9 (47.4)	0
2017	39	26 (66.7)	12 (30.8)	1 (2.6)
2018	10	8 (80.0)	2 (20.0)	0
Age				
<1 yr	30	20 (66.7)	10 (33.3)	0
1 yr	60	41 (68.3)	18 (30.0)	1 (1.7)
2 yrs	12	7 (58.3)	5 (41.7)	0
3 yrs	2	2 (100.0)	0	0
4 yrs	1	1 (100.0)	0	0
Culture				
Positive	11	7 (63.6)	4 (33.4)	0
Negative	94	64 (68.1)	29 (30.9)	1 (1.0)

understanding of the role played by the capsule in the potential of the organism to cause invasive infection.

ACKNOWLEDGMENTS

We have no conflict of interest to disclose.

This study had no funding source.

REFERENCES

1. Yagupsky P. 2015. *Kingella kingae*: carriage, transmission, and disease. Clin Microbiol Rev 28:54–79. <https://doi.org/10.1128/CMR.00028-14>.
2. Porsch EA, Starr KF, Yagupsky P, St Geme JW, 3rd, 2017. The type a and type b polysaccharide capsules predominate in an international collection of invasive *Kingella kingae* isolates. mSphere 2:e00060-17. <https://doi.org/10.1128/mSphere.00060-17>.
3. Starr KF, Porsch EA, Seed PC, Heiss C, Naran R, Forsberg LS, Amit U, Yagupsky P, Azadi P, St Geme JW. 3rd, 2016. *Kingella kingae* expresses four structurally distinct polysaccharide capsules that differ in their correlation with invasive disease. PLoS Pathog 12:e1005944. <https://doi.org/10.1371/journal.ppat.1005944>.
4. Basmaci R, Deschamps K, Levy C, Mathy V, Corrad F, Thollot F, Bechet S, Sobral E, Bidet P, Cohen R, Bonacorsi S. 2018. Prevalence of *Kingella kingae* oropharyngeal carriage and predominance of type a and type b polysaccharide capsules among French young children. Clin Microbiol Infect. <https://doi.org/10.1016/j.cmi.2018.07.033>.
5. Ilharreborde B, Bidet P, Lorrot M, Even J, Mariani-Kurkdjian P, Liguori S, Vitoux C, Lefevre Y, Doit C, Fitoussi F, Pennecot G, Bingen E, Mazda K, Bonacorsi S. 2009. New real-time PCR-based method for *Kingella kingae* DNA detection: application to samples collected from 89 children with acute arthritis. J Clin Microbiol 47:1837–1841. <https://doi.org/10.1128/JCM.00144-09>.